Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Castle Biosciences stock

CSTL
US14843C1053
A2PNH3

Price

28.14
Today +/-
-0.63
Today %
-2.32 %

Castle Biosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Castle Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Castle Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Castle Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Castle Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Castle Biosciences Stock Price History

DateCastle Biosciences Price
12/17/202428.14 undefined
12/16/202428.80 undefined
12/13/202428.87 undefined
12/12/202429.12 undefined
12/11/202429.48 undefined
12/10/202429.63 undefined
12/9/202430.91 undefined
12/6/202431.19 undefined
12/5/202432.16 undefined
12/4/202431.88 undefined
12/3/202430.78 undefined
12/2/202431.40 undefined
11/29/202430.28 undefined
11/27/202430.44 undefined
11/26/202430.57 undefined
11/25/202429.52 undefined
11/22/202429.81 undefined
11/21/202428.88 undefined
11/20/202428.45 undefined
11/19/202428.87 undefined

Castle Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Castle Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Castle Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Castle Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Castle Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Castle Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Castle Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Castle Biosciences’s growth potential.

Castle Biosciences Revenue, EBIT and net profit per share

DateCastle Biosciences RevenueCastle Biosciences EBITCastle Biosciences Net Income
2029e411.47 M undefined28.36 M undefined19.71 M undefined
2028e372.1 M undefined-11.48 M undefined-8.71 M undefined
2027e335.17 M undefined-31.11 M undefined-22.57 M undefined
2026e308.93 M undefined-47.4 M undefined-38.47 M undefined
2025e270.95 M undefined-69.9 M undefined-58.39 M undefined
2024e332.67 M undefined4.04 M undefined10.17 M undefined
2023219.79 M undefined-67.98 M undefined-57.47 M undefined
2022137 M undefined-91.2 M undefined-67.1 M undefined
202194.1 M undefined-40.1 M undefined-31.3 M undefined
202062.6 M undefined-6.5 M undefined-10.3 M undefined
201951.9 M undefined7.3 M undefined3 M undefined
201822.8 M undefined-3.8 M undefined-10.2 M undefined
201713.8 M undefined-10.9 M undefined-15.3 M undefined

Castle Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
1322516294137219332270308335372411
-69.23131.8221.5751.6145.7459.8551.60-18.6714.078.7711.0410.48
61.5477.2786.2785.4882.9876.6479.4552.4164.4456.4951.9446.7742.34
817445378105174000000
-15-103-10-31-67-5710-58-38-22-819
--33.33-130.00-433.33210.00116.13-14.93-117.54-680.00-34.48-42.11-63.64-337.50
161617.118.925.126.126.8000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Castle Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Castle Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
1.24.598.8409.9329.6258.6243.1
4.712.114.612.817.323.538.3
0000000
0.30.91.22.2247.94
0.50.724.84.86.26.29
6.718.2116.6429.7353.7292.3295.64
1.51.52.17.116.926.537.74
0000000
1.62.50.91.11.31.11.19
000088.9115.7106.64
0000010.710.69
0.10.20.11.51.71.11.44
3.24.23.19.7108.8155.1157.71
9.922.4119.7439.4462.5447.4453.34
             
36.146.500000.03
0.80.9137.3478.2505.5560.4609.48
-51.1-57.5-52.2-62.5-93.8-160.9-218.37
00000-400136
0000000
-14.2-10.185.1415.7411.7399.1391.27
1.11.51.92.12.54.710.27
3.15.37.512.120.629.433.85
000.16.71.71.83.48
0000000
105.800.10.10.07
5.26.815.320.924.93647.67
17.624.519.300.10.10.03
0000600400206
1.31.20.12.825.211.514.17
18.925.719.42.825.91214.4
24.132.534.723.750.84862.07
9.922.4119.8439.4462.5447.1453.34
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Castle Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Castle Biosciences's financial health and stability.

Assets

Castle Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Castle Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Castle Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Castle Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-12-65-10-31-67-57
000031012
0000-8-10
0-709-40-6
01218435397
1121000
0000000
-12-1279-18-41-5
000-4-3-5-13
000-4-66-166-16
0000-63-160-2
0000000
8520-27000
01067331400
8158830551-2
0001,0001,0000-2,000
0000000
-3394311-80-206-24
-12.72-12.576.085.12-22.46-47.29-19.25
0000000

Castle Biosciences stock margins

The Castle Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Castle Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Castle Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Castle Biosciences's sales revenue. A higher gross margin percentage indicates that the Castle Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Castle Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Castle Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Castle Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Castle Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Castle Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Castle Biosciences Margin History

Castle Biosciences Gross marginCastle Biosciences Profit marginCastle Biosciences EBIT marginCastle Biosciences Profit margin
2029e79.53 %6.89 %4.79 %
2028e79.53 %-3.08 %-2.34 %
2027e79.53 %-9.28 %-6.73 %
2026e79.53 %-15.34 %-12.45 %
2025e79.53 %-25.8 %-21.55 %
2024e79.53 %1.22 %3.06 %
202379.53 %-30.93 %-26.15 %
202276.64 %-66.57 %-48.98 %
202183.21 %-42.61 %-33.26 %
202084.66 %-10.38 %-16.45 %
201985.93 %14.07 %5.78 %
201876.75 %-16.67 %-44.74 %
201763.77 %-78.99 %-110.87 %

Castle Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Castle Biosciences earnings per share therefore indicates how much revenue Castle Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Castle Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Castle Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Castle Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Castle Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Castle Biosciences Revenue, EBIT and net profit per share

DateCastle Biosciences Sales per ShareCastle Biosciences EBIT per shareCastle Biosciences Earnings per Share
2029e14.69 undefined0 undefined0.7 undefined
2028e13.28 undefined0 undefined-0.31 undefined
2027e11.97 undefined0 undefined-0.81 undefined
2026e11.03 undefined0 undefined-1.37 undefined
2025e9.67 undefined0 undefined-2.08 undefined
2024e11.88 undefined0 undefined0.36 undefined
20238.2 undefined-2.54 undefined-2.14 undefined
20225.25 undefined-3.49 undefined-2.57 undefined
20213.75 undefined-1.6 undefined-1.25 undefined
20203.31 undefined-0.34 undefined-0.54 undefined
20193.04 undefined0.43 undefined0.18 undefined
20181.43 undefined-0.24 undefined-0.64 undefined
20170.86 undefined-0.68 undefined-0.96 undefined

Castle Biosciences business model

Castle Biosciences Inc is an American company that was founded in 2007. The company's goal is to develop and distribute innovative diagnostic tests for various types of cancer. Castle Biosciences is headquartered in Friendswood, Texas, and has numerous branches throughout North America. The company currently has around 200 employees and a strong management team. The business model of Castle Biosciences is based on the development and marketing of personalized medical tests that can help improve the diagnosis and treatment of cancer patients. Castle Biosciences primarily offers its tests through doctors and medical facilities. The company specializes in the development of prognostic and predictive tests that can provide doctors with important information to create personalized treatment plans for their patients. Castle Biosciences has several divisions specializing in different types of cancer. One of the most important divisions is in the field of dermatology, developing and distributing tests for the diagnosis and prognosis of melanoma and other skin cancer types. Castle Biosciences also offers personalized tests for cancer of the eyes, stomach, and lung. Another important product of Castle Biosciences is the DecisionDx-Melanoma test. The test is a molecular diagnostic procedure that predicts the likelihood of melanoma recurrence. The test utilizes proprietary gene expression analysis to assess the risk of melanoma recurrence within five years after tumor removal. The results of the test can help minimize the risk of relapse and improve the patients' quality of life. Castle Biosciences has also developed the DecisionDx-UM test, a diagnostic test for uveal melanoma, a rare cancer affecting the eyes. The DecisionDx-UM test uses RNA expression to predict the individual metastatic risk of the cancer and support optimal medical management. The company has also specialized in the development of tests for gastric cancer. The CastleTest™ analyzes the transcription activity of 11 genes to determine the risk of tumor spread from the primary gastric location. Castle Biosciences has made significant progress in recent years and continues to expand through the introduction of new products and services in the market. The company emphasizes a certification program and continuous training of doctors and pathologists to support test performance. Additionally, Castle Biosciences has brought together additional knowledge and expertise through partnerships with other companies and institutions to develop innovative solutions for a wider range of cancer types. Overall, Castle Biosciences is a company specializing in innovative solutions for the diagnosis and prognosis of cancer. The personalized tests from Castle Biosciences have the potential to improve the quality of life for cancer patients by providing additional information for individual treatment plans. With its dedicated workforce and successful products, Castle Biosciences will continue to play an important role in the fight against cancer. Castle Biosciences is one of the most popular companies on Eulerpool.com.

Castle Biosciences SWOT Analysis

Strengths

Castle Biosciences Inc is a prominent player in the biotechnology industry, known for their innovative products and services.

The company has a strong portfolio of advanced diagnostic tests for skin cancer and other dermatologic conditions, offering reliable and accurate results.

Castle Biosciences Inc has established a solid reputation for their expertise and comprehensive understanding of personalized medicine, which further enhances their market position.

The company's dedicated and skilled team of professionals is a key strength, ensuring high-quality research, development, and customer support.

Weaknesses

One potential weakness for Castle Biosciences Inc is their reliance on a limited range of diagnostic tests. Diversifying their product offerings could help mitigate this risk.

The company may face challenges in terms of regulatory compliance and obtaining necessary approvals for their diagnostic tests, which could result in delays or limitations on market entry.

Castle Biosciences Inc may also be more vulnerable to competition from larger, established biotechnology companies that have greater resources and market presence.

Opportunities

There is a growing demand for personalized medicine and advanced diagnostics, presenting significant opportunities for Castle Biosciences Inc to expand their market share.

The company can explore collaborations and partnerships with healthcare providers and pharmaceutical companies to leverage their expertise and reach a wider customer base.

Expanding into international markets could also be a viable opportunity for Castle Biosciences Inc to broaden their customer reach and increase revenue.

Threats

Competition in the biotechnology industry is intense, with new entrants and established players constantly emerging. Castle Biosciences Inc must stay vigilant and continuously innovate to stay ahead.

Evolving healthcare regulations and policies can pose challenges for Castle Biosciences Inc, as compliance and adherence to these regulations may require significant resources and adaptations.

Market uncertainties and economic fluctuations can also impact the demand for diagnostic tests, making it essential for Castle Biosciences Inc to maintain financial stability and diversify revenue streams.

Castle Biosciences Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Castle Biosciences Revenue by Segment

Segmente202320222021
Dermatologic183.38 M USD124.81 M USD85.75 M USD
Non Dermatologic36.41 M USD--
Other-12.23 M USD8.33 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Castle Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Castle Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Castle Biosciences shares outstanding

The number of shares was Castle Biosciences in 2023 — This indicates how many shares 26.802 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Castle Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Castle Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Castle Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Castle Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Castle Biosciences.

Castle Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.07 0.08  (223.08 %)2024 Q3
6/30/2024-0.27 0.31  (213.14 %)2024 Q2
3/31/2024-0.34 -0.09  (73.4 %)2024 Q1
12/31/2023-0.55 -0.1  (81.72 %)2023 Q4
9/30/2023-0.78 -0.26  (66.62 %)2023 Q3
6/30/2023-0.93 -0.7  (25 %)2023 Q2
3/31/2023-0.91 -1.1  (-21 %)2023 Q1
12/31/2022-0.85 -0.78  (8.7 %)2022 Q4
9/30/2022-0.9 -0.77  (14.22 %)2022 Q3
6/30/2022-0.78 -0.06  (92.28 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Castle Biosciences stock

Eulerpool World ESG Rating (EESG©)

55/ 100

🌱 Environment

63

👫 Social

38

🏛️ Governance

65

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees65.7
Percentage of women in management
Percentage of Asian employees7.2
Share of Asian management
Percentage of Hispanic/Latino employees11.6
Hispano/Latino Management share
Percentage of Black employees2.9
Black Management Share
Percentage of white employees74.2
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Castle Biosciences shareholders

%
Name
Stocks
Change
Date
8.31109 % Wasatch Global Investors Inc2,327,936-223,1526/30/2024
8.06814 % BlackRock Institutional Trust Company, N.A.2,259,885216,7046/30/2024
5.61368 % The Vanguard Group, Inc.1,572,39283,3386/30/2024
5.34860 % Principal Global Investors (Equity)1,498,143-34,3296/30/2024
4.34524 % Bellevue Asset Management AG1,217,101-2,9846/30/2024
4.32328 % Portolan Capital Management, L.L.C.1,210,952167,5426/30/2024
3.78058 % Granahan Investment Management, LLC1,058,941-568,2836/30/2024
3.12249 % Deerfield Management Company, L.P.874,609-53,4086/30/2024
3.04758 % Soleus Capital Management, L.P.853,628128,1716/30/2024
2.89159 % Dimensional Fund Advisors, L.P.809,93460,6756/30/2024
1
2
3
4
5
...
10

Castle Biosciences Executives and Management Board

Mr. Derek Maetzold

(61)
Castle Biosciences President, Chief Executive Officer, Founder, Director (since 2007)
Compensation 7.55 M

Ms. Kristen Oelschlager

(55)
Castle Biosciences Chief Operating Officer
Compensation 2.7 M

Mr. Tobin Juvenal

(63)
Castle Biosciences Chief Commercial Officer
Compensation 2.7 M

Mr. Frank Stokes

(53)
Castle Biosciences Chief Financial Officer
Compensation 2.61 M

Mr. Daniel Bradbury

(62)
Castle Biosciences Independent Chairman of the Board
Compensation 262,555
1
2
3

Most common questions regarding Castle Biosciences

What values and corporate philosophy does Castle Biosciences represent?

Castle Biosciences Inc represents values such as innovation, accuracy, and patient-centricity. With a strong corporate philosophy centered around precision medicine, the company utilizes advanced genomic technology to provide actionable, personalized information to aid healthcare decisions for patients with underserved cancers. Castle Biosciences Inc is committed to improving patient outcomes through its proprietary diagnostic tests that offer valuable insights into the individual biology of each patient. By combining science, research, and a patient-first approach, Castle Biosciences Inc strives to empower healthcare providers and patients with the necessary tools to make informed, targeted treatment decisions.

In which countries and regions is Castle Biosciences primarily present?

Castle Biosciences Inc is primarily present in the United States.

What significant milestones has the company Castle Biosciences achieved?

Castle Biosciences Inc has achieved several significant milestones since its inception. The company pioneered the development of DecisionDx®-Melanoma, a groundbreaking gene expression profile test, which has revolutionized the management of melanoma patients. Castle Biosciences Inc has also expanded its product portfolio with DecisionDx®-UM, a test for uveal melanoma, providing accurate prognostic information for physicians and patients. In addition, the company has received numerous awards and recognitions for its innovative approach to personalized medicine, further establishing its leadership in the field. Castle Biosciences Inc continues to drive advancements in genomic diagnostics, improving patient outcomes and transforming cancer care.

What is the history and background of the company Castle Biosciences?

Castle Biosciences Inc is a leading precision oncology company that specializes in molecular diagnostics. Established in 2008, the company is dedicated to providing personalized medicine solutions for patients with challenging cancers. With a focus on dermatologic cancers, Castle Biosciences utilizes advanced genomic and proteomic technology to develop innovative diagnostic tests. Their flagship product, DecisionDx-Melanoma, is a powerful tool that assesses the risk and prognosis of melanoma patients. Castle Biosciences Inc has a strong commitment to research, collaboration, and improving patient outcomes. With their cutting-edge technology and expertise, the company continues to revolutionize cancer diagnostics and treatment strategies.

Who are the main competitors of Castle Biosciences in the market?

The main competitors of Castle Biosciences Inc in the market are Myriad Genetics, Genomic Health, and NanoString Technologies.

In which industries is Castle Biosciences primarily active?

Castle Biosciences Inc is primarily active in the healthcare industry, specifically in the field of precision medicine. The company specializes in developing and commercializing molecular diagnostics tests that provide personalized genomic information to aid in the diagnosis and treatment of various types of cancer. Castle Biosciences Inc's innovative solutions help healthcare professionals make informed decisions about patient care by assessing the likelihood of disease recurrence and determining optimal treatment plans. With a focus on improving patient outcomes, Castle Biosciences Inc is dedicated to advancing precision medicine in oncology.

What is the business model of Castle Biosciences?

The business model of Castle Biosciences Inc revolves around providing diagnostic and prognostic solutions for patients with skin and other cancers. By leveraging advanced genomic technology, the company offers diagnostic tests that assess the risk, recurrence, and progression of various cancers. Castle Biosciences focuses on developing and commercializing molecular diagnostic tests that aid in personalized treatment decisions for cancer patients. With a patient-centric approach, the company aims to improve patient outcomes and contribute to the advancement of precision medicine. Castle Biosciences Inc is dedicated to revolutionizing cancer management through innovative diagnostics.

What is the P/E ratio of Castle Biosciences 2024?

The Castle Biosciences P/E ratio is 74.15.

What is the P/S ratio of Castle Biosciences 2024?

The Castle Biosciences P/S ratio is 2.27.

What is the Quality Investing of Castle Biosciences?

The Quality Investing for Castle Biosciences is 4/10.

What is the revenue of Castle Biosciences 2024?

The expected Castle Biosciences revenue is 332.67 M USD.

How high is the profit of Castle Biosciences 2024?

The expected Castle Biosciences profit is 10.17 M USD.

What is the business model of Castle Biosciences

Castle Biosciences Inc is a biotechnology company that develops and distributes diagnostic tests and genetic analyses. The company is headquartered in Friendswood, Texas, USA and has been operating in the industry since 2007. The main task of Castle Biosciences is to develop clinically accurate prediction tools to assess the progression of tumors and consider them in patient treatment. For this purpose, the company has developed a range of test procedures based on a combination of genotyping, proteomics, and immuno-sensing methods. The key product of Castle Biosciences is the Prognostic Test, which provides an accurate assessment of the risk of skin cancer. The test uses molecular markers to predict the risk of melanoma or ocular melanoma and determine if therapy is necessary. Another product is DecisionDx-UM, a powerful diagnostic assay that aids in the prognosis of malignant uveal melanoma (UM). In combination with standardized clinical factors such as age, gender, and tumor size, DecisionDx-UM is an important indicator of disease progression as well as promising treatment approaches. Castle Biosciences offers a wide range of proteomic analyses tailored to the needs of the patient. These tests are used to estimate the risk of cancer and enable treating physicians to develop treatment and follow-up strategies. The company also conducts a number of research and development initiatives aimed at understanding the molecular basis of cancer and developing novel diagnostic tests and therapies. The goal is to make groundbreaking scientific discoveries to identify new and improved molecular markers that can be used to assess disease progression and the efficacy of therapies. Overall, Castle Biosciences provides an advanced and accurate platform for cancer diagnostics that can help patients and doctors make better-informed decisions. The company is dedicated to further exploring the molecular basis of cancer and developing more innovative diagnostic tools to improve patient care worldwide. In summary, the business model of Castle Biosciences is focused on the development and marketing of diagnostic tools for cancer treatment. The company offers a wide range of molecular, proteomic, and immuno-sensing analyses that enable accurate prognosis of tumor progression. The company also conducts extensive research and development initiatives to discover new molecular markers for the diagnosis and treatment of cancer.

What is the Castle Biosciences dividend?

Castle Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does Castle Biosciences pay dividends?

The dividend cannot currently be calculated for Castle Biosciences or the company does not pay out a dividend.

What is the Castle Biosciences ISIN?

The ISIN of Castle Biosciences is US14843C1053.

What is the Castle Biosciences WKN?

The WKN of Castle Biosciences is A2PNH3.

What is the Castle Biosciences ticker?

The ticker of Castle Biosciences is CSTL.

How much dividend does Castle Biosciences pay?

Over the past 12 months, Castle Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Castle Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Castle Biosciences?

The current dividend yield of Castle Biosciences is .

When does Castle Biosciences pay dividends?

Castle Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Castle Biosciences?

Castle Biosciences paid dividends every year for the past 0 years.

What is the dividend of Castle Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Castle Biosciences located?

Castle Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Castle Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Castle Biosciences from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Castle Biosciences pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Castle Biosciences in the year 2023?

In the year 2023, Castle Biosciences distributed 0 USD as dividends.

In which currency does Castle Biosciences pay out the dividend?

The dividends of Castle Biosciences are distributed in USD.

All fundamentals about Castle Biosciences

Our stock analysis for Castle Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Castle Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.